Radiographic assessment of nocturnal gastric juice secretion after administration of roxatidine acetate hydrochloride.
Adult patients with symptoms of gastric disease were randomly assigned to a treatment group (n = 103) or untreated control group (n = 89). The treatment group received 75 mg of roxatidine acetate hydrochloride at 9 PM and 12 to 13 hours later gastric juice secretion was measured with gastric x-ray films in both groups. Mean gastric juice secretion was significantly lower in the treated group (16.1 ml/12 hrs) than in the untreated controls (49.8 ml/12 hrs). Gastric juice suppression by roxatidine was 90% in patients with gastric ulcer, 74% in patients with duodenal ulcer, 63% in patients with gastritis, and 70% in patients with no evidence of disease. It is concluded that 150 mg of roxatidine daily would be adequate to treat patients with gastric diseases.
Tanioka
H
H
Department of Radiology, Kanto Rosai Hospital, Kawasaki City, Japan.
Terahara
A
A
Sasaki
Y
Y
D000328:Adult; D005260:Female; D005750:Gastric Juice / Q000378:metabolism*; D005756:Gastritis / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000378:metabolism; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology*
D006635:Histamine H2 Antagonists; D010880:Piperidines; C053742:roxatidine acetate